All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2004-004618-18 | SUBLIVAC® study on the safety of an initial phase rush-in with the use of a compliance friendly one bottle concept. | 2006-06-26 | due-trials |
Reported results | 2005-002859-41 | Open-label, blinded endpoint, randomized, parallel treatment study to compare the clinical efficacy of PURETHAL® Bee and Alutard SQ Bee. | 2008-12-11 | due-trials |
Reported results | 2005-005175-16 | Twin SUBLIVAC® Grasses Clinical Efficay Study | 2009-10-07 | due-trials |
Completed, but no date, and reported results | 2008-006261-81 | Dose Tolerability Study with High Dose PURETHAL Mites in Allergic Rhinitis / Rhinoconjunctivitis Patients. An open study to assess tolerability, safety and short-term efficacy of high dose PURETHAL M... | bad-data | |
Reported results | 2008-006292-77 | SUBLIVAC® Birch PROBE study | 2010-03-02 | due-trials |
Reported results | 2009-015012-18 | A prospective, randomized, open, multi-centre study to assess safety of PURETHAL Grasses given with a rush induction schedule to patients with allergic rhinoconjunctivitis. | 2010-08-24 | due-trials |
Reported results | 2010-021235-13 | A randomized, double-blind, placebo-controlled study to determine safety, tolerability and the optimal effective dose of SUBLIVAC FIX Phleum pratense in patients with allergic rhinitis/rhinoconjunctiv... | 2013-06-24 | due-trials |
Reported results | 2011-000393-61 | A multi-centre, randomized, double-blind, placebo-controlled, dose range finding study to identify the optimal (i.e. safe and effective) dose of PURETHAL® Mites SCIT in patients with house dust mites-... | 2013-05-15 | due-trials |
Reported results | 2011-004550-25 | A randomized, double-blind, placebo-controlled study to determine safety, tolerability and the optimal effective dose of SUBLIVAC FIX Birch in patients with allergic rhinitis/rhinoconjunctivitis cause... | 2013-05-30 | due-trials |
Reported results | 2013-000086-36 | A prospective, randomized, open, multi-centre study to assess safety of PURETHAL Birch given with a rush up-dosing regimen to patients with allergic rhinitis/rhinoconjunctivitis. | 2014-03-28 | due-trials |
Reported results | 2013-005550-30 | A randomized, double-blind, placebo-controlled (DBPC), parallel group study to assess the clinical efficacy and safety of SUBLIVAC FIX Birch immunotherapy in patients suffering from allergic rhinitis/... | 2016-02-03 | due-trials |
Reported results | 2014-002047-18 | A randomized, double-blind, placebo-controlled study to determine tolerability and safety of different dosages of SUBLIVAC FIX Mite mixture in patients with allergic rhinitis / rhinoconjunctivitis cau... | 2015-11-19 | due-trials |
Reported results | 2016-000051-27 | A randomized, double-blind, placebo-controlled (DBPC) parallel-group multi-centre study to assess the efficacy and safety of PURETHAL Mites subcutaneous immunotherapy (SCIT) in patients with allergic ... | 2018-04-23 | due-trials |